마취 및 호흡 기기 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 지역별, 부문별 예측(2025-2030년)

Anesthesia And Respiratory Devices Market Growth & Trends:

The global anesthesia and respiratory devices market size is estimated to reach USD 75.9 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of respiratory diseases, patient preferences for a reduced hospital stay and supportive government funding are among the key driving factors. Furthermore, aging is considered one of the greatest risk factors for the development of sleep apnea disorders and is, therefore, expected to be a high-impact rendering driver for this industry. The COVID-19 pandemic had a significant impact on the industry. Different segments were impacted differently. For instance, the ventilators segment witnessed exponential growth owing to the sudden surge in the demand for mechanical ventilators.

However, this demand decreased post-2021, wherein the industry size decreased dramatically. Concerning the nebulizers segment, people were apprehensive to use nebulizers owing to the use of inhaled medications, which are considered a potential source of viral transmission and immunosuppression, which restricted the growth, but did not negatively impact the industry. Shifting the preference of patients towards reduced hospital stay is anticipated to increase the adoption of anesthesia and breathing instruments, thereby, driving the market. As per the American Hospital Association, approximately 20% of Medicare beneficiaries, when discharged from the hospital return within 30 days. Identifying and reducing avoidable readmissions is expected to improve healthcare safety and reduce spending.

Hence, policymakers are striving to reduce the hospital stays of patients. In the Patient Protection and Affordable Act, Congress initiated the Hospital Readmission Reduction Program (HRRP), under which, Medicare is allowed to penalize hospitals for higher rates of readmissions since 2013. Due to the implementation of this act, many physicians and patients opt for anesthesia and breathing devices, such as ambulatory infusion pumps and home respiratory monitors. Key players are taking initiatives to develop advanced instruments to bring improvement in the treatment. For instance, in May 2022, Max Ventilator launched Non-Invasive (NIV) ventilators consisting of inbuilt humidifiers and oxygen therapy. The device is user-friendly as well as lightweight and is also priced lower than the traditional ventilators. Such initiatives are anticipated to propel industry growth in the coming years.

Anesthesia And Respiratory Devices Market Report Highlights:

• In terms of revenue, the respiratory devices segment held the largest revenue share in 2024, owing to the rising prevalence of Chronic Obstructive Pulmonary Disease (COPD), asthma, and tuberculosis, among others
• The anesthesia devices segment is expected to grow significantly over the forecast period, owing to the rising number of surgeries and various technological advancements by market players
• North America accounted for the largest revenue share in 2024 owing to the presence of major players in the region
• Asia Pacific is expected to witness the fastest CAGR during the forecast period owing to increasing healthcare expenditure and awareness among patients.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Product outlook
  • 1.1.2. Regional scope
  • 1.1.3. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Anesthesia and Respiratory Devices Market Variables, Trends & Scope

• 3.1. Market Dynamics
  • 3.1.1. Market driver analysis
  • 3.1.2. Market restraint analysis
  • 3.1.3. Market Opportunities
• 3.2. Anesthesia and Respiratory Devices Market Analysis Tools
  • 3.2.1. Industry Analysis - Porter's
    • 3.2.1.1. Supplier power
    • 3.2.1.2. Buyer power
    • 3.2.1.3. Substitution threat
    • 3.2.1.4. Threat of new entrant
    • 3.2.1.5. Competitive rivalry
  • 3.2.2. PESTEL Analysis
    • 3.2.2.1. Political landscape
    • 3.2.2.2. Economic landscape
    • 3.2.2.3. Social landscape
    • 3.2.2.4. Technological landscape
    • 3.2.2.5. Environmental landscape
    • 3.2.2.6. Legal landscape
  • 3.2.3. COVID-19 Impact Analysis

Chapter 4. Anesthesia and Respiratory Devices Market: Product Estimates & Trend Analysis

• 4.1. Product Type Market Share, 2023 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Brain Computer Interface Market by Product Type Outlook
  • 4.3.1. Anesthesia Devices
    • 4.3.1.1. Anesthesia Devices market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.1. Anesthesia Machines
        • 4.3.1.1.1.1. Anesthesia Machines market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.1.1.1.2. Anesthesia Workstation
          • 4.3.1.1.1.2.1. Anesthesia Workstation market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.1.1.1.3. Anesthesia Delivery Station
          • 4.3.1.1.1.3.1. Anesthesia Delivery Station market estimates and forecasts, 2018 - 2030 (USD Million)
          • 4.3.1.1.1.3.2. Portable Anesthesia Delivery Station
    • 4.3.1.1.1.3.2.1. Portable Anesthesia Delivery Station market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.1.3.3. Standalone Anesthesia Delivery Station
    • 4.3.1.1.1.3.3.1. Standalone Anesthesia Delivery Station market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.1.4. Anesthesia Ventilators
        • 4.3.1.1.1.4.1. Anesthesia Ventilators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.1.5. Anesthesia Monitors
        • 4.3.1.1.1.5.1. Anesthesia Monitors market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.1.1.2. Anesthesia Disposables
        • 4.3.1.1.2.1. Anesthesia Disposables market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.1.1.2.2. Anesthesia Masks
          • 4.3.1.1.2.2.1. Anesthesia Masks market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.1.1.2.3. Anesthesia Accessories
          • 4.3.1.1.2.3.1. Anesthesia Accessories market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.2. Respiratory Devices
    • 4.3.2.1. Respiratory devices market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1. Respiratory Equipment's
        • 4.3.2.1.1.1. Respiratory Equipment's market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.2. Humidifiers
          • 4.3.2.1.1.2.1. Humidifiers market estimates and forecasts, 2018 - 2030 (USD Million)
          • 4.3.2.1.1.2.2. Heat Humidifiers
    • 4.3.2.1.1.2.2.1. Heat Humidifiers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.2.3. Heated wire breathing circuits
    • 4.3.2.1.1.2.3.1. Heated wire breathing circuits market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.2.4. Heat Exchangers
    • 4.3.2.1.1.2.4.1. Heat Exchangers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.2.5. Pass Over Humidifiers
    • 4.3.2.1.1.2.5.1. Pass Over Humidifiers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.3. Nebulizers
        • 4.3.2.1.1.3.1. Nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.3.2. Pneumatic nebulizers
    • 4.3.2.1.1.3.2.1. Pneumatic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.3.3. Mesh nebulizers
    • 4.3.2.1.1.3.3.1. Mesh nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.3.4. Ultrasonic nebulizers
    • 4.3.2.1.1.3.4.1. Ultrasonic nebulizers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.4. Oxygen Concentrators
        • 4.3.2.1.1.4.1. Oxygen Concentrators market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.4.2. Fixed Oxygen Concentrators
    • 4.3.2.1.1.4.2.1. Fixed Oxygen Concentrators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.4.3. Portable Oxygen Concentrators
    • 4.3.2.1.1.4.3.1. Portable Oxygen Concentrators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.5. Positive airway pressure devices
        • 4.3.2.1.1.5.1. Positive airway pressure devices market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.5.2. Bi-level positive airway pressure devices
    • 4.3.2.1.1.5.2.1. Bi-level positive airway pressure devices market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.5.3. Continuous positive airway pressure devices
    • 4.3.2.1.1.5.3.1. Continuous positive airway pressure devices market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.6. Reusable resuscitators
        • 4.3.2.1.1.6.1. Reusable resuscitators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.7. Ventilators
        • 4.3.2.1.1.7.1. Ventilators market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.7.2. Adult Ventilators
    • 4.3.2.1.1.7.2.1. Adult Ventilators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.7.3. Neonatal Ventilators
    • 4.3.2.1.1.7.3.1. Neonatal Ventilators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.8. Respiratory inhalers
        • 4.3.2.1.1.8.1. Respiratory inhalers market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.8.2. Dry Powdered Inhalers
    • 4.3.2.1.1.8.2.1. Dry Powdered Inhalers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.8.3. Meter Dose Inhalers
    • 4.3.2.1.1.8.3.1. Meter Dose Inhalers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.9. Respiratory disposable
        • 4.3.2.1.1.9.1. Respiratory disposable market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.9.2. Disposable Oxygen Mask
    • 4.3.2.1.1.9.2.1. Disposable oxygen mask market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.9.3. Resuscitators
    • 4.3.2.1.1.9.3.1. Resuscitators market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.9.4. Tracheostomy Tubes
    • 4.3.2.1.1.9.4.1. Tracheostomy Tubes market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.9.5. Oxygen Cannula
    • 4.3.2.1.1.9.5.1. Oxygen Cannula market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.10. Respiratory measurement devices
        • 4.3.2.1.1.10.1. Respiratory measurement devices market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.3.2.1.1.10.2. Pulse oximetry systems
    • 4.3.2.1.1.10.2.1. Pulse oximetry systems market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.10.3. Capnographs
    • 4.3.2.1.1.10.3.1. Capnographs market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.10.4. Spirometers
    • 4.3.2.1.1.10.4.1. Spirometers market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.3.2.1.1.10.5. Peak flowmeters
    • 4.3.2.1.1.10.5.1. Peak flowmeters market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5. Anesthesia and Respiratory Devices Market: Regional Estimates & Trend Analysis, By Product

• 5.1. Regional Market Share Analysis, 2023 & 2030
• 5.2. Regional Market Dashboard
• 5.3. Global Regional Market Snapshot
• 5.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 5.5. North America
  • 5.5.1. U.S.
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Canada
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. Mexico
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Europe
  • 5.6.1. UK
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. Germany
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. France
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Italy
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Regulatory framework/ reimbursement structure
    • 5.6.4.3. Competitive scenario
    • 5.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.5. Spain
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Regulatory framework/ reimbursement structure
    • 5.6.5.3. Competitive scenario
    • 5.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Norway
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Regulatory framework/ reimbursement structure
    • 5.6.6.3. Competitive scenario
    • 5.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.7. Sweden
    • 5.6.7.1. Key country dynamics
    • 5.6.7.2. Regulatory framework/ reimbursement structure
    • 5.6.7.3. Competitive scenario
    • 5.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.8. Denmark
    • 5.6.8.1. Key country dynamics
    • 5.6.8.2. Regulatory framework/ reimbursement structure
    • 5.6.8.3. Competitive scenario
    • 5.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Asia Pacific
  • 5.7.1. Japan
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. China
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.3. India
    • 5.7.3.1. Key country dynamics
    • 5.7.3.2. Regulatory framework/ reimbursement structure
    • 5.7.3.3. Competitive scenario
    • 5.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.4. Australia
    • 5.7.4.1. Key country dynamics
    • 5.7.4.2. Regulatory framework/ reimbursement structure
    • 5.7.4.3. Competitive scenario
    • 5.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.5. South Korea
    • 5.7.5.1. Key country dynamics
    • 5.7.5.2. Regulatory framework/ reimbursement structure
    • 5.7.5.3. Competitive scenario
    • 5.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.6. Thailand
    • 5.7.6.1. Key country dynamics
    • 5.7.6.2. Regulatory framework/ reimbursement structure
    • 5.7.6.3. Competitive scenario
    • 5.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Latin America
  • 5.8.1. Brazil
    • 5.8.1.1. Key country dynamics
    • 5.8.1.2. Regulatory framework/ reimbursement structure
    • 5.8.1.3. Competitive scenario
    • 5.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Argentina
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Regulatory framework/ reimbursement structure
    • 5.8.2.3. Competitive scenario
    • 5.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. MEA
  • 5.9.1. South Africa
    • 5.9.1.1. Key country dynamics
    • 5.9.1.2. Regulatory framework/ reimbursement structure
    • 5.9.1.3. Competitive scenario
    • 5.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.2. Saudi Arabia
    • 5.9.2.1. Key country dynamics
    • 5.9.2.2. Regulatory framework/ reimbursement structure
    • 5.9.2.3. Competitive scenario
    • 5.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.3. UAE
    • 5.9.3.1. Key country dynamics
    • 5.9.3.2. Regulatory framework/ reimbursement structure
    • 5.9.3.3. Competitive scenario
    • 5.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9.4. Kuwait
    • 5.9.4.1. Key country dynamics
    • 5.9.4.2. Regulatory framework/ reimbursement structure
    • 5.9.4.3. Competitive scenario
    • 5.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Key company market share/position analysis, 2023
• 6.4. Company Profiles
  • 6.4.1. General Electric Company
    • 6.4.1.1. Company Overview
    • 6.4.1.2. Financial Performance
    • 6.4.1.3. Product Benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Medtronic
    • 6.4.2.1. Company Overview
    • 6.4.2.2. Financial Performance
    • 6.4.2.3. Product Benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Teleflex Incorporated
    • 6.4.3.1. Company Overview
    • 6.4.3.2. Financial Performance
    • 6.4.3.3. Product Benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Koninklijke Philips N.V.
    • 6.4.4.1. Company Overview
    • 6.4.4.2. Financial Performance
    • 6.4.4.3. Product Benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Dragerwerk AG & CO. KGAA
    • 6.4.5.1. Company Overview
    • 6.4.5.2. Financial Performance
    • 6.4.5.3. Product Benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. Getinge AB
    • 6.4.6.1. Company Overview
    • 6.4.6.2. Financial Performance
    • 6.4.6.3. Product Benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Smiths Group PLC
    • 6.4.7.1. Company Overview
    • 6.4.7.2. Financial Performance
    • 6.4.7.3. Product Benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Fisher & Paykel Healthcare Limited
    • 6.4.8.1. Company Overview
    • 6.4.8.2. Financial Performance
    • 6.4.8.3. Product Benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. Masimo
    • 6.4.9.1. Company Overview
    • 6.4.9.2. Financial Performance
    • 6.4.9.3. Product Benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Braun Melsungen AG
    • 6.4.10.1. Company Overview
    • 6.4.10.2. Financial Performance
    • 6.4.10.3. Product Benchmarking
    • 6.4.10.4. Strategic initiatives
  • 6.4.11. ResMed
    • 6.4.11.1. Company Overview
    • 6.4.11.2. Financial Performance
    • 6.4.11.3. Product Benchmarking
    • 6.4.11.4. Strategic initiatives
  • 6.4.12. Inogen, Inc.
    • 6.4.12.1. Company Overview
    • 6.4.12.2. Financial Performance
    • 6.4.12.3. Product Benchmarking
    • 6.4.12.4. Strategic initiatives
  • 6.4.13. Caire Medical (a subsidiary of NGK Spark Plug)
    • 6.4.13.1. Company Overview
    • 6.4.13.2. Financial Performance
    • 6.4.13.3. Product Benchmarking
    • 6.4.13.4. Strategic initiatives
  • 6.4.14. DeVilbiss Healthcare (a subsidiary of Drive Medical)
    • 6.4.14.1. Company Overview
    • 6.4.14.2. Financial Performance
    • 6.4.14.3. Product Benchmarking
    • 6.4.14.4. Strategic initiatives
  • 6.4.15. React Health (Respiratory Product Line from Invacare Corporation)
    • 6.4.15.1. Company Overview
    • 6.4.15.2. Financial Performance
    • 6.4.15.3. Product Benchmarking
    • 6.4.15.4. Strategic initiatives
  • 6.4.16. O2 Concepts
    • 6.4.16.1. Company Overview
    • 6.4.16.2. Financial Performance
    • 6.4.16.3. Product Benchmarking
    • 6.4.16.4. Strategic initiatives
  • 6.4.17. Nidek Medical Products, Inc.
    • 6.4.17.1. Company Overview
    • 6.4.17.2. Financial Performance
    • 6.4.17.3. Product Benchmarking
    • 6.4.17.4. Strategic initiatives
  • 6.4.18. Omron Corporation
    • 6.4.18.1. Company Overview
    • 6.4.18.2. Financial Performance
    • 6.4.18.3. Product Benchmarking
    • 6.4.18.4. Strategic initiatives
  • 6.4.19. GE Healthcare
    • 6.4.19.1. Company Overview
    • 6.4.19.2. Financial Performance
    • 6.4.19.3. Product Benchmarking
    • 6.4.19.4. Strategic initiatives
  • 6.4.20. Allied Healthcare
    • 6.4.20.1. Company Overview
    • 6.4.20.2. Financial Performance
    • 6.4.20.3. Product Benchmarking
    • 6.4.20.4. Strategic initiatives
  • 6.4.21. Vectura Group Plc.
    • 6.4.21.1. Company Overview
    • 6.4.21.2. Financial Performance
    • 6.4.21.3. Product Benchmarking
    • 6.4.21.4. Strategic initiatives
  • 6.4.22. PARI Respiratory Equipment, Inc.
    • 6.4.22.1. Company Overview
    • 6.4.22.2. Financial Performance
    • 6.4.22.3. Product Benchmarking
    • 6.4.22.4. Strategic initiatives
  • 6.4.23. Aerogen
    • 6.4.23.1. Company Overview
    • 6.4.23.2. Financial Performance
    • 6.4.23.3. Product Benchmarking
    • 6.4.23.4. Strategic initiatives
  • 6.4.24. DeVilbiss Healthcare LLC
    • 6.4.24.1. Company Overview
    • 6.4.24.2. Financial Performance
    • 6.4.24.3. Product Benchmarking
    • 6.4.24.4. Strategic initiatives
  • 6.4.25. Briggs Healthcare
    • 6.4.25.1. Company Overview
    • 6.4.25.2. Financial Performance
    • 6.4.25.3. Product Benchmarking
    • 6.4.25.4. Strategic initiatives
  • 6.4.26. Beurer GmBH
    • 6.4.26.1. Company Overview
    • 6.4.26.2. Financial Performance
    • 6.4.26.3. Product Benchmarking
    • 6.4.26.4. Strategic initiatives